title: Impact of Dry Mouth on Fluid Intake and Overactive Bladder Symptoms in Women taking Fesoterodine.
abstract: OBJECTIVE
  We investigated the long-term relationships between dry mouth, fluid intake and overactive bladder symptoms in women undergoing treatment with fesoterodine. We hypothesized that women who experienced dry mouth would increase their fluid intake and worsen their urinary symptoms.
  
  
  METHODS
  We conducted a prospective ancillary study to a 9-month open-label trial of fesoterodine for women with urgency urinary incontinence. Fluid intake was measured and compared according to reported dry mouth. Multivariable analysis was used to study the interaction between dry mouth, fluid intake and urinary symptoms.
  
  
  RESULTS
  During the study 407 women without dry mouth significantly reduced their fluid intake (mean decrease 172.1 ml, median 118.3 ml, p = 0.02), while 91 women with dry mouth did not (mean decrease 95.8 ml, median 118.3 ml, p = 0.54). On univariable analysis a greater proportion of women who experienced dry mouth reported improvement in their urinary symptoms compared to women without dry mouth (60.5% vs 47.2%, p = 0.03). On multivariable analysis black women were less likely to report dry mouth (OR 0.4, 95% CI 0.2-0.9, p = 0.03) and older women were less likely to report improvement in urinary symptoms (OR 0.98, 95% CI 0.96-0.99, p = 0.003). Factors not associated with improvement in urinary symptoms on multiple regression were dry mouth, baseline fluid intake volume, change in fluid intake volume and caffeine intake volume.
  
  
  CONCLUSIONS
  In women with overactive bladder receiving fesoterodine dry mouth may prevent restriction of fluid intake but does not diminish treatment efficacy.
authors.affiliation: Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Steven.Weissbart@uphs.upenn.edu.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Weissbart
authors.affiliation: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Rusell
authors.initials: R
authors.lastname: Lewis
authors.affiliation: Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Ariana L
authors.initials: AL
authors.lastname: Smith
authors.affiliation: Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Heidi S
authors.initials: HS
authors.lastname: Harvie
authors.affiliation: Department of Health Behavior and Biological Sciences, School of Nursing, and Department of Obstetrics and Gynecology, School of Medicine, University of Michigan, Ann Arbor, Michigan.
authors.forename: Janis M
authors.initials: JM
authors.lastname: Miller
authors.affiliation: Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Lily A
authors.initials: LA
authors.lastname: Arya
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004326:Drinking; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009059:Mouth Diseases / Q000175:diagnosis / Q000209:etiology*; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects*
chemical_list: D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; C526675:fesoterodine
keywords: caffeine; urinary bladder, overactive; urinary incontinence, urge; water-electrolyte balance; xerostomia